We are pleased to report yet another consistent quarter of strong revenue growth for our three approved therapies – EXONDYS 51, VYONDYS 53 and AMONDYS 45 – achieving total revenue of $210.8 million dollars and net product revenues approaching $190 million. Our net product revenue performance represents a growth rate of over 50% as compared to the same quarter last year. The AMONDYS 45 launch continues to excel, and each of our three approved therapies – EXONDYS 51, VYONDYS 53 and AMONDYS 45 – contributed to our exceptional growth rate,” said Doug Ingram, Sarepta’s president and CEO. Mr. Ingram continued, “Sarepta is well positioned to thrive, largely agnostic to the challenging external market environment. We are advancing our significant multi-platform pipeline, with strong positive readouts across platforms, and we continue to enroll and dose patients in our global phase 3 pivotal studies for our lead gene therapy candidate, the EMBARK study for SRP-9001, and our lead next-generation RNA therapy, the MOMENTUM study for our PPMO SRP-5051. In addition to our strong revenue performance, we exited the first quarter with over $2 billion on our balance sheet to invest in bringing a better life to the patient communities we serve.”
USD
- Forums
- ASX - By Stock
- PER
- For General Information
For General Information, page-237
-
- There are more pages in this discussion • 3,290 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
|
|||||
Last
7.8¢ |
Change
-0.002(2.50%) |
Mkt cap ! $70.32M |
Open | High | Low | Value | Volume |
7.6¢ | 7.8¢ | 7.5¢ | $32.58K | 429.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 253224 | 7.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.0¢ | 253231 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 253224 | 0.075 |
3 | 360708 | 0.074 |
1 | 100000 | 0.072 |
2 | 310000 | 0.071 |
7 | 58616 | 0.070 |
Price($) | Vol. | No. |
---|---|---|
0.080 | 253231 | 2 |
0.081 | 100000 | 1 |
0.082 | 255785 | 2 |
0.083 | 110520 | 2 |
0.084 | 57142 | 1 |
Last trade - 14.56pm 22/07/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |